Sientra to Report Third Quarter 2022 Financial Results on November 10, 2022

Rhea-AI Summary

Sientra, Inc. (NASDAQ: SIEN) announced the release of its third quarter 2022 financial results, set to take place after market closure on November 10, 2022. A conference call to discuss these results will follow at 4:30 p.m. ET. The company focuses on medical aesthetics and offers innovative plastic surgery products, including the FDA-approved fifth-generation breast implants and the Allox2® tissue expander. Interested parties can access the conference call via dial-in or webcast.

Positive

• Innovation in product offerings with FDA-approved fifth-generation breast implants.
• Strong clinical trial results supporting product portfolio.

Negative

• None.

SANTA BARBARA, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that it will release financial results for the third quarter of 2022 after the close of trading on Thursday, November 10, 2022. Sientra will host a conference call to discuss financial results the same day at 4:30 p.m. Eastern Time.

The dial-in numbers are 1-866-374-5140 for domestic callers. The conference ID is 57765123#. The webcast link is the following: Sientra Q3' 2022 Earnings Call Webcast Registration Link.

A live webcast of the conference call will be available on the Investor Relations section of the Company's website at www.sientra.com. The webcast will be archived on the website following the completion of the call.  

About Sientra
Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company exclusively focused on plastic surgery. The Company mission is to offer proprietary innovations and unparalleled partnerships that radically advance how plastic surgeons think, work and care for their patients. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company’s product portfolio includes its Sientra round and shaped breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2® breast tissue expander with patented dual-port and integral drain technology, the AuraGen fat grafting system, and BIOCORNEUM®, the #1 performing, preferred and recommended scar gel of plastic surgeons(*).

Sientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Company’s investor relations website at www.sientra.com.

^(*)  Data on file

Investor Relations Contact
Aman R. Patel, CFA
aman.patel@westwicke.com

FAQ

When will Sientra announce its Q3 2022 financial results?

Sientra will announce its Q3 2022 financial results after market close on November 10, 2022.

What time is Sientra's Q3 2022 earnings conference call?

The conference call will take place at 4:30 p.m. Eastern Time on November 10, 2022.

How can I listen to Sientra's Q3 2022 earnings call?

You can listen to the earnings call via dial-in at 1-866-374-5140 or via the webcast link available on their investor relations website.

What products does Sientra offer?

Sientra offers a range of products including fifth-generation breast implants, the Allox2® breast tissue expander, and the AuraGen fat grafting system.